17 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22620 | any line, RECIST 1.1 | Ahmad Hussein Awada | Multiple | Boehringer Ingelheim | 1367.1 | Trial closed | An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22626 | Germ cell tumor | Thierry Gil | Testicles | EORTC | 1407 GUCC TIGER | Trial closed for recruitment | A Randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high dose chemotherapy using mobilizing paclitaxel plus ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors | thierry.gil@hubruxelles.be | 3 | 3 | |
| 22632 | any line, RECIST 1.1 | Philippe Aftimos | Multiple | Amcure GmbH | AMC303-01 | Trial closed | A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin | philippe.aftimos@hubruxelles.be | 1/1b | 1 | |
| 22775 | second line metastatic | Thierry Gil | Multiple | EORTC | ANITA | Trial closed | A phase II multicenter study comparing the efficacy of the oral angiogenesis inhibitor nintedanib with the intravenous cytotoxic compound ifosfamide for treatment of patients with advanced metastatic soft tissue sarcoma after failure of systemic non-oxazaphosphorine-based first line chemotherapy for inoperable disease | thierry.gil@hubruxelles.be | 2 | 2 | |
| 22719 | Breast implants | Marie Maerevoet | Lymphoma | Lymphoma Academic Research Organization | BIA-ALCL | Trial open for recruitment | Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry | marie.maerevoet@hubruxelles.be | |||
| 29645 | Thierry Gil | sarcome | Boehringer Ingelheim | Brightline-1 | Trial closed for recruitment | A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma (Brightline-1 ; 1403-0008) | thierry.gil@hubruxelles.be | 2/3 | 2 | ||
| 22692 | any line / Lung metastasis | Konstantinos Stathopoulos | Lung | EORTC | EORTC 1658 | Trial closed | Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) | konstantinos.stathopoulos@hubruxelles.be | |||
| 22627 | after standard therapy | Thierry Gil | Soft tissue | Epizyme | EZH-202 | Trial closed | A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma | thierry.gil@hubruxelles.be | 2 | 2 | |
| 22850 | Metastatic, any tumors | Solid tumors | Institut Jules Bordet | IJB_2728 | Trial open for recruitment | Improving emotion regulation for patients with metastatic cancer: A pilot study assessing the impact of a multi-component psychological group intervention | |||||
| 22849 | Be a parent or close relative of a child between the ages of 3 and 18 confronted with parental cancer, any tumors | Solid tumors | Intervention destinée aux parents | Trial open for recruitment | L'enfant face au cancer d'un parent: une étude randomisée évaluant l'efficacité d'une intervention psychologique destinée à soutenir la parentalité | ||||||
| 22612 | *Radiological progression RECIST 1.1 over the last 12 months *Disease progression on a PET/CT or SPECT/CT over the last 12 months *at least one lesion with hight tumour uptake on Ga-octreotate PET/CT and morphologically measurable according to RECIST1.1 |
Patrick Flamen | Multiple | Institut Jules Bordet | LuMEn | Trial closed | The LuMEn study 177Lu-octreotate treatment outcome prediction using Multimodality imaging in refractory neuroEndocrine tumours | patrick.flamen@hubruxelles.be | 3 | 3 | |
| 22749 | Subject is able to receive radiotherapy and surgery | sarcome | Nanobiotix | NBTXR3-301 Nanobiotix | Trial closed | A multicentre randomized, open-label Phase II/III study, to compare the efficacy of NBTXR3, implanted as intratumor injection and activated by radiotherapy, versus radiotherapy alone in patients with locally advanced soft tissue sarcoma of the extremity and trunk wall | 2/3 | 2 | |||
| 22728 | RECIST v1.1 | Christiane Jungels | Soft tissue | SpringWorks Therapeutics | NIR-DT-301 | Trial closed | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors (DTs)/Aggressive Fibromatosis (AF) | christiane.jungels@hubruxelles.be | 3 | 3 | |
| 22675 | Any line/RECIST v1.1/Eligible for platinium salt chemotherapy | Nuria Kotecki | Multiple | Onxeo | OX2016-203-01 | Trial closed | An open-label, dose-escalation, phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors | Nuria.Kotecki@hubruxelles.be | 1 | 1 |